A review of human and analogue insulin trials

Diabetes Research and Clinical Practice

Volumn 77, Issue 1, 2007, Pages 1-15

  Gough, Stephen C L ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Hypoglycaemia; Insulin analogues; Postprandial glucose

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INSULIN; INSULIN, ISOPHANE; POSTPRANDIAL PERIOD; RANDOMIZED CONTROLLED TRIALS;

EID: 34247149764     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.10.015     Document Type: Review

References (66)

1. Plank J., Siebenhofer A., Berghold A., Jeitler K., Horvath K., Mrak P., et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch. Intern. Med. 165 (2005) 1337-1344
2. A. Siebenhofer, J. Plank, A. Berghold, M. Narath, R. Gfrerer, T. Pieber, Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus, Cochrane Database Syst. Rev. 18 (2004) CD003287.
3. Pfutzner A., Kustner E., and Forst T. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp. Clin. Endocrinol. Diabetes 104 (1996) 25-30
4. Anderson J.H., Brunelle R.L., Koivisto V.A., Pfutzner A., Trautmann M.E., Vignati L., et al. Reduction of postprandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment. Diabetes 46 (1997) 265-270
5. Anderson J.H., Brunelle R.L., Koivisto V.A., Trautmann M.E., Vignati L., and DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin. Ther. 19 (1997) 62-72
6. Holleman F., Schmitt H., Rottiers R., Rees A., Symanowski S., and Anderson J.H. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 20 (1997) 1827-1832
7. Heller S.R., Amiel S.A., and Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care 22 (1999) 1607-1611
8. Holcombe J.H., Zalani S., Arora V.K., Mast C.J., and Lispro in Adolescents Study Group. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin. Ther. 24 (2002) 629-638
9. Valle D., Santoro D., Bates P., Scarpa L., and Italian Multicentre Lispro Study Group. Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with Type 1 diabetes. Diabetes Nutr. Metab. 14 (2001) 126-132
10. Home P., Lindholm A., Riis A., and European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet. Med. 17 (2000) 762-770
11. Home P.D., Hallgren P., Usadel K.H., Sane T., Faber J., Grill V., et al. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Res. Clin. Pract. 71 (2006) 131-139
12. Raskin P., Guthrie R., Leiter L., Riis A., and Jovanic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23 (2000) 583-588
13. Heller S.R., Colagiuri S., Vaaler S., Wolffenbuttel B.H., Koelendorf K., Friberg H.H., et al. Hypoglycaemia with insulin aspart: a double-blind, randomized, crossover trial in subjects with type 1 diabetes. Diabet. Med. 21 (2004) 769-775
14. Garg S.K., Rosenstock J., and Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr. Pract. 11 (2005) 11-17
15. Raskin P., Klaff L., Bergenstal R., Halle J.P., Donley D., and Mecca T. 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23 (2000) 1666-1671
16. Ratner R.E., Hirsch I.B., Neifing J.L., Garg S.K., Mecca T.E., and Wilson C.A. Less hypoglycaemia with IGlarg in intensive insulin therapy for type 1 diabetes. Diabetes Care 23 (2000) 639-643
17. Porcellati F., Rossetti P., Pampanelli S., Fanelli C.G., Torlone E., Scionti L., et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet. Med. 21 (2004) 1213-1220
18. Schober E., Schoenle E., Van Dyk J., Wernicke-Panten K., and Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care 24 (2001) 2005-2006
19. Fulcher G.R., Gilbert R.E., and Yue D.K. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern. Med. J. Sep. 35 9 (2005) 536-542
20. Home P.D., Rosskamp R., Forjanic-Klapproth J., Dressler A., and European Insulin Glargine Study Group. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab. Res. Rev. 21 (2005) 545-553
21. Vague P., Selam J.L., Skeie S., De Leeuw I., Elte J.W., Haahr H., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26 (2003) 590-596
22. De Leeuw I., Vague P., Selam J.-L., Skeie S., Lang H., Draeger E., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes. Metab. 7 (2005) 73-82
23. Standl E., Lang H., and Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol. Ther. 6 (2004) 579-588
24. Pieber T.R., Draeger E., Kristensen A., and Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet. Med. 22 (2005) 850-857
25. Home P., Bartley P., Russell-Jones D., Hanaire-Broutin H., Heeg J.E., Abrams P., et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 27 (2004) 1081-1087
26. Russell-Jones D., Simpson R., Hylleberg B., Draeger E., and Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin. Ther. 26 (2004) 724-736
27. Kolendorf K., Prasek M., and Santeusanio F. Insulin detemir is associated with lower risk of hypoglycaemia compared to NPH insulin in people with type 1 diabetes. Diabetologia 47 Suppl. 1 (2004) A329 (Abstract)
28. Robertson K., Schönle E., Gucev Z., Mordhorst L., Tamer S., Gall M.-A., et al. Benefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes: lower and more predictable fasting plasma glucose and lower risk nocturnal hypoglycaemia. Diabetolgia 47 Suppl. 1 (2004) A32 (Abstract)
29. Hermansen K., Fontaine P., Kukolja K., Peterkova V., Leth G., and Gall M.-A. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47 (2004) 622-629
30. K. Raslova, M. Bogoev, I. Raz, G. Leth, M.A. Gall, N. Hancu, Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes, Diabetes Res. Clin. Pract. 66 (2004) 193-201
31. See also Erratum, Diabetes Res. Clin. Pract., 72 (1) 2006 112.
32. Haak T., Tiengo A., Draeger E., Suntum M., and Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes. Metab. 7 (2005) 56-64
33. Hermansen K., Derezinski T., Kim H., and Gall M.-A. Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with type 2 diabetes. Diabetologia 47 Suppl. 1 (2004) A273 (Abstract)
34. Yki-Jarvinen H., Dressler A., Ziemen M., and HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes, HOE 901/3002 Study Group. Diabetes Care 23 (2000) 1130-1136
35. Rosenstock J., Schwartz S.L., Clark Jr. C.M., Park G.D., Donley D.W., and Edwards M.B. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
36. Fritsche A., Schweitzer M.A., and Häring H.-U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann. Intern. Med. 138 (2003) 952-959
37. Riddle M., Rosenstock J., and Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
38. Eliaschewitz F.G., Calvo C., Valbuena H., Ruiz M., Aschner P., Villena J., et al. Latin American clinical trial project on insulin glargine versus NPH plus glimepiride in type 2 diabetes. Diabetologia 46 Suppl. 2 (2003) A273 (Abstract)
39. Heise T., Nosek L., Ronn B.B., Endahl L., Heinemann L., Kapitza C., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 (2004) 1614-1620
40. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients. Diabetes Care 26 (2003) 881-885
41. Ashwell S., Amiel S., Bilous R., Dashora U., Heller S.R., Hepburn D.A., et al. Improved blood glucose control with insulin glargine plus insulin lispro in comparison with NPH insulin plus unmodified human insulin in people with type 1 diabetes. Diabet. Med. 23 (2006) 285-292
42. Murphy N.P., Keane S.M., Ong K.K., Ford-Adams M., Edge J.A., Acerini C.L., et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 26 (2003) 799-804
43. Boehm B.O., Home P.D., Behrend C., Kamp N.M., and Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet. Med. 19 (2002) 393-399
44. Boehm B.O., Vaz J.A., Brønstedt L., and Home P.D. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur. J. Intern. Med. 15 (2004) 496-502
45. Roach P., Yue L., and Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 22 (1999) 1258-1261
46. McNally P., Fitch M., and Nelson G. Patients with type 2 diabetes mellitus have lower rates of nocturnal hypoglycaemia on biphasic insulin aspart (BIAsp 30) than on biphasic human insulin-30 (BHI30): data from the REACH study. Diabetologia 47 Suppl. 1 (2004) A327 (Abstract)
47. Iwamoto Y. A randomised, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes. Diabetologia 46 Suppl. 2 (2003) A270 (Abstract)
48. Massi Benedetti M., Humburg E., Dressler A., and Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm. Metab. Res. 35 (2003) 189-196
49. Rosenstock J., Dailey G., Massi-Benedetti M., Fritsche A., Lin Z., and Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28 (2005) 950-955
50. Anderson Jr. J.H., Brunelle R.L., Keohane P., Koivisto V.A., Trautmann M.E., Vignati L., et al., Multicenter Insulin Lispro Study Group. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch. Intern. Med. 157 (1997) 1249-1255
51. Ross S.A., Zinman B., Campos R.V., Strack T., and Canadian Lispro Study Group. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin. Invest. Med. 24 (2001) 292-298
52. Dailey G., Rosenstock J., Moses R.G., and Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27 (2004) 2363-2368
53. Brunelle B.L., Llewelyn J., Anderson Jr. J.H., Gale E.A., and Koivisto V.A. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21 (1998) 1726-1731
54. Heller S., Kim H., and Draeger E. Within-person variation in fasting blood glucose is correlated to incidence of hypoglycaemia in people with type 1 diabetes treated with insulin detemir and NPH insulin. Diabetes 53 Suppl. 2 (2004) A486 (Abstract)
55. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 54 (2005) 1-7
56. DECODE Study Group on Behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 354 (1999) 617-621
57. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., and STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003) 486-494
58. American Association of Clinical Endocrinologists, Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement, 2005, Available from http://www.aace.com/meetings/consensus/odimplementation/PositionStatement.pdf, accessed 9 December 2005.
59. American Association of Clinical Endocrinologists Road Map to Achieve Glycaemic Goals, 2005, Available from http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf, accessed 9 December 2005.
60. Raskin P., Allen E., Hollander P., Lewin A., Gabbay R.A., Hu P., et al. Initiating insulin therapy in type 2 diabetes. Diabetes Care 28 (2005) 260-265
61. Diabetes Control and Complications Trial Research Group. Hypoglycaemia in the diabetes control and complications trial. Diabetes 46 (1997) 271-286
62. Tamas G., Marre M., Astorga R., Dedov I., Jacobsen J., Lindholm A., and Insulin Aspart Study Group. Glycaemic control in Type 1 diabetic patients using optimized insulin aspart or human insulin in a randomized multinational study. Diabetes Res. Clin. Pract. 54 (2001) 105-114
63. Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life?. Diabet. Med. 12 (1995) 449-450
64. Brunner G.A., Hirschberger S., Sendlhofer G., Wutte A., Ellmerer M., Balent B., et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet. Med. 17 (2000) 371-375
65. Dunn C.J., and Plosker G.L. Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus. Pharmacoeconomics 20 (2002) 989-1025
66. Bott U., Ebrahim S., Hirschberger S., and Skovlund S.E. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes. Diabet. Med. 20 (2003) 626-634